F

Fulcrum Therapeutics

D
FULC
USD
-0.01
(-0.2865%)
Market Open
16,287.00
Volume
-0.15
EPS
-
Div Yield
-10.205882
P/E
216,530,671.90
Market Cap
Today
-0.5731%
1 Week
9.810%
1 Month
-2.801%
6 Months
-53.979%
12 Months
-19.208%
Year To Date
-48.593%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

EV Maker Fisker Files for Bankruptcy

18.06.2024
Stocks news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news

Tesla Sales Drop Amid Intensifying EV Competition

03.04.2024
Stocks news

EV Maker Fisker in Grave Trouble as Shares Tank

27.03.2024
Stocks news
More
Related Instruments
-0.0001352587
(-0.3671%)
USD

Title:
Fulcrum Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Do you need help or have a question?
Contact Us